Causes of Drug-Induced Severe Cutaneous Adverse Reaction Epidermal Necrolysis (EN): An Analysis Using FDA Adverse Event Reporting System (FAERS) Database

References

• Heng YK, Lee HY, Roujeau J-C. Epidermal necrolysis: 60 years of errors and advances. Br J Dermatol. 2015;173(5):1250–1254. doi:10.1111/bjd.13989
   PubMed Web of Science ®Google Scholar
• Hsu DY, Brieva J, Silverberg NB, et al. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–1397. doi:10.1016/j.jid.2016.03.023
   PubMed Web of Science ®Google Scholar
• Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240–1247. doi:10.1016/j.jid.2017.01.031
   PubMed Web of Science ®Google Scholar
• Yang M-S, Lee JY, Kim J, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea. PLoS One. 2016;11(11):e0165933. doi:10.1371/journal.pone.0165933
   PubMed Web of Science ®Google Scholar
• Abou-Taleb DAE, El-Sayed AM, Ghabesha AA, et al. Severe cutaneous adverse drug reactions: incidence, clinical patterns, causative drugs and modalities of treatment in Assiut University Hospital, Upper Egypt. Dermatol Ther. 2020;33(6):e14176. doi:10.1111/dth.14176
   PubMed Web of Science ®Google Scholar
• Paulmann M, Mockenhaupt M. Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. Allergo J Int. 2019;28(8):311–326. doi:10.1007/s40629-019-00111-8
   Google Scholar
• Gupta LK, Martin AM, Agarwal N, et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: an Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82(6):603–625. doi:10.4103/0378-6323.191134
   PubMed Web of Science ®Google Scholar
• Zhang J, Lei Z, Xu C, et al. Current perspectives on severe drug eruption. Clin Rev Allergy Immunol. 2021;61(3):282–298. doi:10.1007/s12016-021-08859-0
   PubMed Web of Science ®Google Scholar
• Lucia L, Silvia C, Paolo B, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson Syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;90:52–60.
   Google Scholar
• Edinoff AN, Nguyen LH, Fitz-Gerald MJ, et al. Lamotrigine and Stevens-Johnson syndrome prevention. Psychopharmacol Bull. 2021;51(2):96–114.
   PubMedGoogle Scholar
• Lavu A, Thiriveedi S, Thomas L, et al. Clinical Utility of HLA-B*58:01 Genotyping to Prevent Allopurinol-Induced SJS/TEN. Hosp Pharm. 2021;56(6):660–663. doi:10.1177/0018578720934972
   PubMed Web of Science ®Google Scholar
• Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219–1232. doi:10.1111/all.12260
   PubMed Web of Science ®Google Scholar
• Asyraf PA, Kusnadi IF, Stefanus J, et al. Clinical manifestations and genetic influences in sulfonamide-induced hypersensitivity. Drug Healthc Patient Saf. 2022;14:113–124. doi:10.2147/DHPS.S347522
   PubMed Web of Science ®Google Scholar
• Peter J, Choshi P, Lehloenya RJ. Drug Hypersensitivity in HIV Infection. Curr Opin Allergy Clin Immunol. 2019;19(4):272. doi:10.1097/ACI.0000000000000545
   PubMed Web of Science ®Google Scholar
• Budamakuntla L, Challa N, Basappa P, et al. A retrospective study of spectrum of nevirapine induced cutaneous drug reactions in HIV positive patients. UCMS. 2015;12:85–89.
   Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi:10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Schöpf E, Stühmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. an epidemiologic study from West Germany. Arch Dermatol. 1991;127(6):839–842. doi:10.1001/archderm.1991.01680050083008
   PubMedGoogle Scholar
• Lim VM, Do A, Berger TG, et al. A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic epidermal necrolysis: clinical pathological diagnosis and risk factor awareness. Burns. 2016;42(4):836–843. doi:10.1016/j.burns.2016.01.014
   PubMed Web of Science ®Google Scholar
• Maloney NJ, Ravi V, Cheng K, et al. Stevens‐Johnson Syndrome and toxic epidermal necrolysis‐like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol. 2020;59(6):e183–e188. doi:10.1111/ijd.14811
   PubMed Web of Science ®Google Scholar
• Dasanu CA. Late-Onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. J Oncol Pharm Pract. 2019;25(8):2052–2055. doi:10.1177/1078155219830166
   PubMed Web of Science ®Google Scholar
• Hong D, Sloane DE. Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases. Ann Allergy Asthma Immunol. 2019;123(1):35–41. doi:10.1016/j.anai.2019.04.015
   PubMed Web of Science ®Google Scholar
• Robinson S, Saleh J, Curry J, et al. Pembrolizumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: a case report. Am J Dermatopathol. 2020;42(4):292–296. doi:10.1097/DAD.0000000000001527
   PubMed Web of Science ®Google Scholar
• Cao J, Li Q, Zhi X, et al. Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report. Transl Cancer Res. 2021;10(8):3870–3876. doi:10.21037/tcr-21-470
   PubMed Web of Science ®Google Scholar
• Gallo Marin B, Oliva R, Kahn B, et al. Pembrolizumab-induced toxic epidermal necrolysis in a patient with metastatic esophageal adenocarcinoma. R I Med J. 2022;105:34–36.
   Google Scholar
• Lee O, Masood M, Nutan F. Case series of Stevens-Johnson syndrome and toxic epidermal necrolysis with nivolumab and nivolumab/ipilimumab combination therapy in metastatic melanoma. J Drugs Dermatol. 2022;21(5):529–530. doi:10.36849/JDD.6559
   PubMed Web of Science ®Google Scholar
• Mockenhaupt, 11 human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond – PMC. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676067/. Accessed February 7, 2023.
   Google Scholar
• Lin C-Y, Wang C-W, Hui C-YR. Delayed‐type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T‐cell reactivity study. Allergy. 2018;73(1):221–229. doi:10.1111/all.13235
   PubMed Web of Science ®Google Scholar
• Frey N, Bodmer M, Bircher A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: a population-based case–control study. Drug Saf. 2019;42(1):55–66. doi:10.1007/s40264-018-0711-x
   PubMed Web of Science ®Google Scholar
• Kim M-H, Kang DY, Nam Y-H, et al. Clinical aspects of severe cutaneous adverse reactions caused by beta-lactam antibiotics: a study from the Korea SCAR Registry. World Allergy Organ J. 2023;16(1):100738. doi:10.1016/j.waojou.2022.100738
   PubMed Web of Science ®Google Scholar